Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. - Wikidata - wikimedia - TriplyDB

Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile.

Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile.

http://www.wikidata.org/entity/Q34439843

about

Low prevalence of liver-kidney microsomal autoantibodies of type 1 (LKM1) in hepatitis C seropositive subjects on Crete, Greece The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease Immunoglobulin GM and KM Allotypes and Prevalence of Anti-LKM1 Autoantibodies in Patients with Hepatitis C Virus Infection Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics Autoantibodies in chronic hepatitis C: A clinical perspective Potential viral pathogenic mechanism in human type 1 diabetes Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane.Verification of B-lymphocyte activating factor's involvement in the exacerbation of insulin resistance as well as an autoimmune response in patients with nonalcoholic steatohepatitis and patients with HCV-related chronic liver disease The cytoskeleton of digestive epithelia in health and disease.Autoantibodies and liver disease: uses and abuses.Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-alpha Is autoimmune hepatitis a frequent finding among HCV patients with intense interface hepatitis?Review article: autoimmune hepatitis -- current management and challenges.Autoimmune hepatitis and its variant syndromes.Genetic distinctions between autoimmune hepatitis in Italy and North America.Recurrent acute hepatitis associated with use of cetirizine.Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: a pilot study Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection.Autoimmune hepatitis: a review of current diagnosis and treatment.Meta-analysis: diagnostic accuracy of antinuclear antibodies, smooth muscle antibodies and antibodies to a soluble liver antigen/liver pancreas in autoimmune hepatitis.Clinical significance of the detection of antinuclear antibodies in patients with acute hepatitis a.The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis.Management of chronic hepatitis C.Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders.Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection.Thyroid Peroxidase Antibodies in Non-Interferon Treated Hepatitis C Patients in Pakistan.Management of patients with difficult autoimmune hepatitis.Autoimmune hepatitis as a unique form of an autoimmune liver disease: immunological aspects and clinical overview.Autoantibodies and autoimmune disease during treatment of children with chronic hepatitis C.Study of non-organ-specific antibodies in children with genotype 4 chronic hepatitis C.Autoantibody profiles in autoimmune hepatitis and chronic hepatitis C identifies similarities in patients with severe disease.Infectious serologies and autoantibodies in hepatitis C and autoimmune disease-associated mixed cryoglobulinemia.Polyreactive antibodies in adaptive immune responses to viruses.Autoimmune manifestations in viral hepatitis.Host factors determining the efficacy of hepatitis C treatment.Clinical aspects of indirect immunofluorescence for autoimmune diseases.Autoantibodies in liver disease: important clues for the diagnosis, disease activity and prognosis.

P2860

Q24799970-EB61C7B5-8882-4E6E-8C71-07293ACD352A Q24801439-C2C8186B-CAFF-4FB1-A240-F304E5B8F3B2 Q24804699-BB76DBBD-84F7-4DC6-92EF-013E83320178 Q27473220-0848A708-C6F0-4BDD-BC01-EFC6507D0E23 Q27477841-B85E49D3-4601-45E2-98ED-606F353DD359 Q28087726-9F7B5EC7-A3A5-4F61-A81E-B8F8CE0BD704 Q28088556-A84F1DD9-2B60-43F2-9378-5C840E074F0D Q28656023-8BA29AC9-F5DD-47EA-A3F6-DAC2C2B168C9 Q30846833-A2D48423-EC07-439E-B698-C7FFFEEF7517 Q33795637-A7E3191B-4306-43CD-A02F-3BA465E3FD6B Q33796503-9C4DE671-D947-4A5A-9E4B-DBC83A4C0184 Q33829963-D5DB2013-AF50-42FE-837F-EF011266D9D6 Q33909777-5B808282-9DFF-44E5-81DB-F6435CF4907A Q34041429-F67947FE-4BF2-44D6-9FB2-A48D0EC383CA Q34369116-5CA83713-994E-4F07-9320-7803C876EFFC Q34371115-33295BE6-194C-4C4B-80CB-ADB11A1BC061 Q34406835-96809A99-20D1-4212-88A6-16F43E24B7EF Q34551111-05DD3811-AFAD-49F7-A983-5EB023A8FC52 Q34605699-3E9B4E1C-747F-4ABC-9E50-1F3C9E9EB3DA Q34626547-B88BE755-98D2-4D05-898B-7BBD71CB36DE Q35094267-E5CCF678-2AF5-4CC5-AD8E-1C21D3B2463F Q35126088-1AC8F239-834F-4D0D-A5BA-2BC95D5D3F4B Q35195460-F1CF5A2C-BDB1-4F2C-83EC-296CF859D0DA Q35350742-35FE19F5-DAF1-46A8-9817-90539215B295 Q35522138-754A9735-FFAB-459B-BE87-CE550BE7AD4D Q35769853-835AD97C-9391-4D92-85F7-E7EA55F4F7FD Q35914823-BAC12309-AD4F-4696-9468-274CBE7322E5 Q36231193-F3B8332C-C613-4B65-AD99-5EAAF01E9EB8 Q36285235-7E56EE9F-73A8-468C-89D6-0B1B799B539F Q36379083-C5B30BBA-1661-403A-92B2-9D1C739A0535 Q36490242-250F3FED-CD7F-4158-85EB-6AC02A1D6C20 Q36641415-FF07C320-9982-4332-8065-5D6411F9FED0 Q37645723-8E79B888-B683-4E7A-9A6F-477CCAB3C84A Q37672213-B73BFA9D-8075-40B8-9EC5-0E9F2EDC03C5 Q37883979-774610AF-0B80-486F-87E1-D3A8CF26B7ED Q37951868-7C20E18D-2FEE-451D-B0C4-019DBDA9F719 Q38046450-0E94BBA8-5939-47AF-8612-2CF76803E7CF Q38056077-B618AF31-5329-4DB8-848C-45AA00BF53A5 Q38382986-A99A64AE-F3A8-4399-8811-143506B27F69 Q38497449-0E05A0E3-8F36-4603-8EE4-041FC3DC78FB

P2860

Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile.

http://www.wikidata.org/entity/Q34439843

description

1997 nî lūn-bûn

@nan

1997 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

1997 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

name

Serum autoantibodies in chroni ...... impact on the disease profile.

@ast

Serum autoantibodies in chroni ...... impact on the disease profile.

@en

Serum autoantibodies in chroni ...... impact on the disease profile.

@nl

type

label

Serum autoantibodies in chroni ...... impact on the disease profile.

@ast

Serum autoantibodies in chroni ...... impact on the disease profile.

@en

Serum autoantibodies in chroni ...... impact on the disease profile.

@nl

prefLabel

Serum autoantibodies in chroni ...... impact on the disease profile.

@ast

Serum autoantibodies in chroni ...... impact on the disease profile.

@en

Serum autoantibodies in chroni ...... impact on the disease profile.

@nl

P1433

Q34439843-5C573C6A-AB47-4A62-A374-1E58A01E188D

P1476

Q34439843-9F12FD3A-56DB-4432-A884-95CE972047CA

P2093

Q34439843-0C32D5A1-2B1B-4BA9-9099-87DFE7C902A7

Q34439843-1E48451F-26AC-4D14-B864-098F9B52521D

Q34439843-415C3A50-062F-4495-A81D-292F5CCB64E9

Q34439843-53E90B18-13B7-425C-8F24-EA4B356FE7F1

Q34439843-67CCDC8F-93D8-4A20-BE9D-F2470F9CA3B4

Q34439843-6DDA0701-8864-4315-BD39-C1C7CCD2373F

Q34439843-8A3DBA14-D959-4333-B30A-B206938AD6A7

Q34439843-8FECE029-24B0-48DC-9E2D-EF8F6DB60A93

Q34439843-ACF5D4A7-0477-4A48-ABB2-51D81A3CEA86

Q34439843-E8734277-DBE7-4D2D-913F-66A2EE585ED9

P304

Q34439843-A42AEDDB-A57B-424E-A670-C0E29D495C72

P31

Q34439843-EDD3F07D-43CC-43AC-AF18-8C0577E01388

P356

Q34439843-41837B3D-C020-44C2-8C69-68EE663EBCDF

P407

Q34439843-CE17414E-8AFA-459D-9B90-22758982C8F6

P433

Q34439843-E035B8A3-45DC-4DC0-B934-8CD08B574326

P478

Q34439843-86AA5707-53DB-4AC5-A141-5B1F467155F2

P577

Q34439843-0C78B4F3-E8DA-4D1E-9351-8791AD65D633

P5875

Q34439843-70CBA6F7-DBF2-4F2E-8B5A-1D71398A5444

P698

Q34439843-B7E05924-177B-465C-A881-77B426D980D2

P921

Q34439843-83D3BC1A-E4E5-45E1-8869-E28B3B7BAAD7

P356

P1433

P1476

Serum autoantibodies in chroni ...... impact on the disease profile.

@en

P2093

Bianchi FB

http://www.w3.org/2001/XMLSchema#string

Bianchi G

http://www.w3.org/2001/XMLSchema#string

Cassani F

http://www.w3.org/2001/XMLSchema#string

Cataleta M

http://www.w3.org/2001/XMLSchema#string

Francesconi R

http://www.w3.org/2001/XMLSchema#string

Giostra F

http://www.w3.org/2001/XMLSchema#string

Lenzi M

http://www.w3.org/2001/XMLSchema#string

Muratori L

http://www.w3.org/2001/XMLSchema#string

Muratori P

http://www.w3.org/2001/XMLSchema#string

Valentini P

http://www.w3.org/2001/XMLSchema#string

P304

561-566

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.510260305

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

1997-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13917084

http://www.w3.org/2001/XMLSchema#string

P698

9303483

http://www.w3.org/2001/XMLSchema#string

P921